David Wallace, MD, MPH, serves as chair for the IU School of Medicine Department of Ophthalmology and director of the Eugene and Marilyn Glick Eye Institute. A native Hoosier and IU School of Medicine alumnus, Dr. Wallace joined the department from Duke University where he served as a professor of ophthalmology and pediatrics, vice chair for clinical strategic planning and director for clinical research. Prior to joining the faculty at Duke, Dr. Wallace served as the ophthalmology residency program director at the University of North Carolina for six years where he also obtained a master's degree in public health in epidemiology.

Dr. Wallace's primary research interests are retinopathy of prematurity (ROP), amblyopia and clinical trials. He served a five-year term as chair of the Pediatric Eye Disease Investigator Group (PEDIG), a National Institutes of Health-funded, national clinical research network, and he currently leads multicenter studies of low-dose bevacizumab for ROP. 

Dr. Wallace has lectured internationally and has authored or co-authored more than 160 scientific publications. He has served as senior associate editor for the Journal of the American Association of Pediatric Ophthalmology and Strabismus, and as president of the North Carolina Society of Eye Physicians and Surgeons. Read more about Dr. Wallace in this Q&A. 

Chair's Welcome

Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME, Kong L, Holmes JM; Pediatric Eye Disease Investigator Group (PEDIG). Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol 2017;135:654-656.

Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT; Pediatric Eye Disease Investigator Group. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. Ophthalmology 2018;125:1961-1966.

Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, Yang MB, Rogers DL, Hutchinson AK, VanderVeen DK, Haider KM, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Kong L, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group (PEDIG). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol 2020;138:698-701.